Harbin Pharmaceutical Group Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	2.1yrs
Board average tenure	2.4yrs

Recent management updates

Recent updates

Harbin Pharmaceutical Group Co., Ltd. (SHSE:600664) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 25

Investors Aren't Buying Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Earnings

Jun 25

We Think Harbin Pharmaceutical Group (SHSE:600664) Can Manage Its Debt With Ease

May 25

Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think

Apr 17

CEO

Harbin Pharmaceutical Group has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Bo Jiang	CFO & VP	3.8yrs	CN¥1.31m	no data
Xiaodong Meng	VP & Secretary	less than a year	CN¥1.31m	0.013% CN¥ 1.2m
Haitao Jiang	Vice President	2.6yrs	CN¥691.90k	0.0019% CN¥ 184.2k
Jicheng Xia	Vice President	2.1yrs	CN¥467.60k	0.0032% CN¥ 306.7k
Bangdong Li	Vice President	2.1yrs	CN¥578.60k	0.0016% CN¥ 153.4k

2.1yrs

Average Tenure

51yo

Average Age

Experienced Management: 600664's management team is considered experienced (2.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Aidong Lou	Independent Director	3.8yrs	CN¥150.00k	no data
Weihong Lu	Independent Director	3.8yrs	CN¥150.00k	no data
Zhaohua Li	Independent Director	3.8yrs	CN¥150.00k	no data
Ying Lei	Independent Director	less than a year	no data	no data
Xiaoping Hu	Chairman	3.8yrs	no data	no data
Shiwei Yin	Director	2.8yrs	no data	no data
Zhifeng Sun	Director	2.4yrs	no data	no data
Fangju Qiu	Employee Supervisor	less than a year	no data	0.000080% CN¥ 7.7k
Liu Mo	Director	less than a year	no data	no data
Cheng Peng	Supervisor	less than a year	no data	no data
Wenguang Peng	Chairman of the Supervisory Board	less than a year	no data	no data

2.4yrs

Average Tenure

49yo

Average Age

Experienced Board: 600664's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Harbin Pharmaceutical Group Management

Management criteria checks 1/4

Key information

Recent management updates

High number of new and inexperienced directors

Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 07, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.061 (vs CN¥0.053 in 3Q 2023)

Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 22%

Harbin Pharmaceutical Group Co., Ltd. (SHSE:600664) Looks Inexpensive But Perhaps Not Attractive Enough

Second quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.022 in 2Q 2023)

High number of new and inexperienced directors

Investor sentiment improves as stock rises 18%

Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Investors Aren't Buying Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Earnings

We Think Harbin Pharmaceutical Group (SHSE:600664) Can Manage Its Debt With Ease

Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 07, 2024

First quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.05 in 1Q 2023)

Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think

Full year 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.19 in FY 2022)

Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

New minor risk - Financial data availability

Investor sentiment deteriorates as stock falls 18%

Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 11, 2024

Third quarter 2023 earnings released: EPS: CN¥0.053 (vs CN¥0.012 in 3Q 2022)

Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.15 in FY 2021)

Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.012 (vs CN¥0.06 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.009 (vs CN¥0.12 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.03 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.15 (vs CN¥0.43 loss in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.014 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.06 loss in 2Q 2020)

Ecmoho Limited and Harbin Pharmaceutical Group Announce Joint Launch of New Iron Supplement Product

First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.07 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.43 loss per share (vs CN¥0.02 profit in FY 2019)

Harbin Pharmaceutical Group Co., Ltd.(XSSC:600664) dropped from S&P Global BMI Index

New 90-day low: CN¥2.84

New 90-day low: CN¥3.09

New 90-day low: CN¥3.22

Third quarter earnings released

New 90-day low: CN¥3.33

Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

First half earnings released

Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age